| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
SciSparc Ltd.$4.71
-0.07 (-1.46%)
D 25Pipeline Score Fair Value Pharma · Clinical
Market Cap
2.45 M
EPS
-231.49
P/E Ratio
-
Value Trade
1.67 M
-14.6 %
Week
-24.29 %
1 Month
-16.49 %
3 Month
-79.68 %
6 Month
-99.98 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
12.01 K
52 Week Range
2.98 - 80.10
% held by Insiders
1.85 %
% held by Institutions
0.57 %
Enterprise Value
-889.25 K
Total Shares
573.17 K
Short %
3.44 %
Float Shares
454.53 K
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for SciSparc Ltd.
320Total events
1Upcoming
86Tier-1 (high impact)
2017 – 2026Coverage
Upcoming catalysts 1
Event history 319
Jun 4, 2026
Jun 1, 2026
◆Other Regulator MilestoneEx-US Regulatory
Outside date for completion of Transaction extended to June 1, 2026
May 28, 2026
▲Other Regulator MilestoneEx-US Regulatory
NeuroThera received conditional regulatory approval from TSX for acquisition of 54% interest in CliniQuantum
Apr 30, 2026
●Partnership / LicenseCorporate
Amendment to SPA to address TSX comment on minimum price and lock-up arrangements
Mar 16, 2026
●Composition Patent FiledIP / Competition
Patent application filed for MEAI-PEA combination therapy for MDD
major depressive disordersource ↗
Mar 12, 2026
▲Patent GrantedIP / Competition
Publication of international patent application for MEAI-PEA combination therapy
weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD)source ↗
Mar 10, 2026
◆AcquisitionCorporate
NeuroThera signs definitive agreement to acquire 54.01% stake in CliniQuantum
Mar 8, 2026
▲Product LaunchMUSEPost-Market
SciSparc intends to commence commercialization of MUSE system immediately after transaction closing
gastroesophageal reflux disease (GERD)source ↗
Mar 4, 2026
Mar 2026
▲Partnership / LicenseCorporate
NeuroThera entered into share purchase agreement to acquire 54% of CliniQuantum
Feb 2, 2026
▲Patent GrantedIP / Competition
U.S. patent granted for cannabinoid-enhanced antimicrobial platform
antimicrobial resistance (MRSA)source ↗
Drug Pipeline Intelligence
D25
Pipeline Score $4M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.7x
rNPV / MCap Top 24%
Micro Cap (rank 690 of 906)
Percentile RankSciSparc Ltd. faces pipeline headwinds (25/100), with $320M risk-adjusted pipeline value, led by Dronabinol and Palmitoylethanolamide in Tourette Syndrome (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dronabinol and Palmitoylethanolamide Small molecule | Tourette Syndrome | Phase 2 | NCT03066193 | 27% | $160M | COMPLETED | 17 | - | - | Jun 28, 2018 | - | Feb 24, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Combination Treatment | obesity and related metabolic disorders | Preclinical | 2023-11-28 | increased metabolic activity; reduced appetite; enhanced fat oxidation; 84 animals; 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI; 25 mg/kg of PEA; increased oxygen consumption; carbon dioxide emission; elevated energy expenditure; notable reduction in food consumption; 40 and 20 mg/kg of MEAI Read More | SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment Read More | |
Combination Treatment | obesity and related metabolic disorders | Preclinical | 2023-11-28 | increased metabolic activity; reduced appetite; enhanced fat oxidation; 84 animals; 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI; 25 mg/kg of PEA; increased oxygen consumption; carbon dioxide emission; elevated energy expenditure; notable reduction in food consumption; 40 and 20 mg/kg of MEAI Read More | SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment Read More | |
Combination Treatment | obesity and related metabolic disorders | Preclinical | 2023-11-28 | increased metabolic activity; reduced appetite; enhanced fat oxidation; 84 animals; 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI; 25 mg/kg of PEA; increased oxygen consumption; carbon dioxide emission; elevated energy expenditure; notable reduction in food consumption; 40 and 20 mg/kg of MEAI Read More | SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SPRC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SPRC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SPRCSciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has completed the acquisition of a 54% interest in CliniQuantum. This acquisition, valued at approximately CAD$9.46 million, aims to leverage CliniQuantum's technology for improving clinical trial outcomes. The deal includes potential earn-out payments based on future milestones, highlighting the strategic focus on central nervous system disorders.
Read more →SPRCSciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, received conditional regulatory approval from the TSX for acquiring a 54% interest in CliniQuantum. The acquisition involves issuing approximately 56.6 million common shares of NeuroThera to CliniQuantum's shareholders. This strategic move aims to enhance NeuroThera's capabilities in developing novel treatments for central nervous system disorders.
Read more →SPRCSciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
SciSparc Ltd. has announced a collaboration with NeuroThera Labs and Clearmind Medicine, resulting in a patent application for a new therapy targeting major depressive disorder. This innovative treatment combines MEAI and PEA, potentially offering a non-hallucinogenic alternative to traditional antidepressants. The patent filing highlights the promise of this combination in addressing depression, a major global health concern.
Read more →SPRCSciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
SciSparc Ltd. announced a collaboration with NeuroThera Labs and Clearmind Medicine to publish an international patent for a novel therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD). The combination therapy of MEAI and PEA aims to provide a safer alternative to existing treatments. This development comes amid a rapidly growing market for weight loss drugs, projected to reach $226 billion by 2035.
Read more →SPRCSciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has signed a definitive agreement to acquire a 54.01% stake in CliniQuantum. This acquisition aims to leverage CliniQuantum's quantum technology to enhance clinical trial processes. The transaction is valued at approximately $9.46 million, with additional earn-out payments based on specific milestones. The closing is expected to occur within 30 days after applying for an Israeli tax ruling, anticipated around March 31, 2026.
Read more →SPRCSciSparc Announces 1-for-9 Reverse Share Split
SciSparc Ltd. announced a one-for-nine reverse share split effective March 4, 2026. Following the split, the company will have approximately 565,000 outstanding shares, with no changes to shareholders' ownership percentages. The split aims to improve the company's stock price and market perception while maintaining its Nasdaq trading symbol.
Read more →SPRCSciSparc Announces 1-for-9 Reverse Share Split Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Tel Aviv, Israel
SciSparc Ltd. announced a 1-for-9 reverse share split effective on March 4, 2026. After the split, the company will hold approximately 565,000 outstanding shares, with about 561,533 publicly held. The decision was approved by shareholders at the Annual General Meeting held on June 26, 2025, and is intended to adjust the share structure without altering ownership percentages significantly. No fractional shares will be issued as a result of the split, and trading will continue under the existing symbol 'SPRC'.
Read more →SPRCSciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
SciSparc Ltd. announced that NeuroThera Labs has been granted a U.S. patent for a novel cannabinoid-enhanced platform aimed at overcoming antibiotic resistance, specifically targeting MRSA. This technology combines traditional antibiotics with cannabinoids to enhance their effectiveness against resistant bacterial strains. The patent strengthens NeuroThera's intellectual property and addresses the urgent need for innovative solutions in the face of rising antimicrobial resistance.
Read more →SPRCSciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
SciSparc Ltd. has successfully completed the acquisition of an intellectual property portfolio from Xylo Technologies, which includes the MUSE™ endoscopic system for treating GERD. The company plans to immediately commercialize these technologies and aims to replicate Xylo's successful licensing model in high-growth markets like North America and Europe. The global GERD device market is projected to grow significantly by 2030.
Read more →SPRCSciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
SciSparc Ltd. has signed a definitive agreement to acquire a portfolio of patents for innovative endoscopic systems, including the MUSE™ system. The company plans to commercialize these technologies immediately after the transaction closes on March 8, 2026. This acquisition aims to replicate Xylo Technologies' successful commercialization model in high-growth markets like North America and Europe. The global GERD device market is projected to grow significantly, presenting a lucrative opportunity for SciSparc.
Read more →SPRCSciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
SciSparc Ltd. has received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirements. The company reported negative equity of approximately $(81,000) as of June 30, 2025. SciSparc has until February 26, 2026, to submit a compliance plan, with expectations to meet requirements by December 31, 2025, following recent funding.
Read more →SPRCSciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
SciSparc Ltd. announced that NeuroThera Labs has received a patent from the Israeli Patent Office for its opioid-based technology aimed at enhancing pain relief while minimizing side effects. This patent complements existing patents in other countries, reinforcing the intellectual property of the proprietary drug combination. Pre-clinical studies indicate that the combination of opioids and N-acylethanolamines can improve analgesic effects and reduce adverse reactions.
Read more →SPRCSciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has signed a non-binding term sheet to acquire a 55% stake in a quantum computing bio data analysis company. This acquisition aims to leverage quantum technologies to enhance clinical analytics and bioinformatics. However, the deal is contingent upon due diligence and regulatory approvals, with no guarantee of completion.
Read more →SPRCSciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
SciSparc Ltd. has signed a binding term sheet to acquire a portfolio of patents and intellectual property rights for the MUSE™ system, an endoscopic device for treating GERD. The company aims to replicate Xylo Technologies' successful commercialization model in Greater China across North America, Europe, and Latin America. The global GERD device market is projected to grow significantly, presenting substantial revenue opportunities.
Read more →SPRCSciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
SciSparc Ltd. has signed a binding term sheet to acquire a portfolio of patents and intellectual property for innovative endoscopic systems from Xylo Technologies. This includes the MUSE™ system designed for treating gastroesophageal reflux disease (GERD). The company aims to replicate Xylo's successful commercialization model in new markets such as North America and Europe, potentially unlocking substantial revenue streams.
Read more →SPRCSciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
SciSparc Ltd. has announced a new Israeli patent application in collaboration with Clearmind Medicine for a novel treatment targeting depression. This innovative therapy combines 5-methoxy-2-aminoindane and N-Acylethanolamines. The collaboration has resulted in 13 patents focused on various conditions, including depression, with promising preclinical data supporting its efficacy.
Read more →SPRCSCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4
SCISPARC LTD. has released its interim consolidated financial statements for the six months ended June 30, 2025. The financial performance shows a significant operating loss amounting to $9.4 million, reflecting an increase in research and development expenses and general administrative costs. The company's accumulated deficit has grown to over $84 million, raising concerns over financial stability. Current liabilities surpass current assets, indicating potential liquidity problems for the company. Overall, the financial statements depict a challenging period for SCISPARC as it navigates increasing losses and a deteriorating equity position.
Read more →SPRCSciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
SciSparc Ltd. has completed the acquisition of Neurothera Labs Inc., gaining a controlling interest and transferring its advanced clinical stage pharmaceutical portfolio. The total enterprise value of Neurothera is approximately $3.3 million, while the Target Assets are valued at $11.6 million. This acquisition positions SciSparc to enhance its focus on cannabinoid pharmaceuticals.
Read more →SPRCSciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
SciSparc Ltd. has finalized the sale of its majority-owned subsidiary, MitoCareX, to N2OFF, enhancing its focus on drug discovery for resistant cancers. The deal includes a purchase of shares and milestone-based stock issuances for the sellers. MitoCareX aims to develop therapies targeting mitochondrial proteins, potentially advancing treatment options for challenging cancers.
Read more →SPRCSciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
SciSparc Ltd. has announced the launch of a new initiative aimed at utilizing quantum computing for 3D protein modeling. This program seeks to enhance drug discovery by improving the accuracy of protein structure predictions. The company plans to form a dedicated research team and collaborate with experts in the field, focusing on applications for neurological and rare diseases.
Read more →SPRCSciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
SciSparc Ltd. announced a collaboration with Clearmind Medicine Inc. that has resulted in the publication of a U.S. patent application for a novel therapy targeting binge behavior disorders. The patent covers a combination of MEAI and N-Acylethanolamines, aiming to address issues like excessive alcohol consumption and eating disorders. This innovative approach may offer a safer alternative to traditional interventions.
Read more →SPRCSciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
SciSparc Ltd. has entered into a definitive agreement to acquire a controlling interest in Miza III Ventures Inc. and transfer its advanced clinical stage pharmaceutical portfolio. The total enterprise value of Miza is approximately US$3.3 million, while the Target Assets are valued at about US$11.6 million. The transaction is expected to close around October 22, 2025, pending regulatory approvals.
Read more →SPRCMIZA III VENTURES INC. and SCISPARC LTD. ASSET AND SHARE PURCHASE AGREEMENT OCTOBER 9, 2025 TABLE OF CONTENTS Part 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Schedules 9 1.3 Interpretation 9 1.4 Governing Law 10 1.5 Severa
Miza III Ventures Inc. has entered into an asset and share purchase agreement with SciSparc Ltd., outlining the terms of the transaction. The agreement includes detailed definitions, conditions for closing, and the allocation of purchase price among the purchased assets. Various representations, warranties, covenants, and indemnities are stipulated for both parties, ensuring mutual agreement and understanding. The completion of the transaction is subject to several conditions and legal provisions detailed in the agreement.
Read more →SPRCSciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
SciSparc Ltd. has entered into a framework agreement to mutually terminate its merger with AutoMax Motors. This agreement resolves previous commitments and establishes repayment terms for outstanding loans. AutoMax is set to repay a total of $6.25 million in loans to SciSparc, with specific repayment schedules outlined.
Read more →SPRCFRAMEWORK AGREEMENT This Framework Agreement (the " Agreement ") is dated as of
SciSparc Ltd. and AutoMax Motors Ltd. entered a Framework Agreement to mutually terminate their Merger Agreement, originally signed on April 10, 2024. The agreement includes amended terms for repayment concerning earlier loans totaling $6.25 million, following the Borrower's failure to make required payments. The revised repayment of the Bridge Loan Amount is set for January 1, 2028, while the New Loan Amount will be repaid in monthly installments starting November 20, 2025. The agreement emphasizes the Lender's right to enforce immediate repayment due to default conditions.
Read more →SPRCSciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
SciSparc Ltd. announced that N2OFF shareholders approved the acquisition of its subsidiary MitoCareX, which specializes in drug discovery for resistant cancers. This acquisition is a significant step for MitoCareX, allowing it to become a wholly owned subsidiary of N2OFF. The deal includes financial support for MitoCareX's operations and milestone-based stock issuances.
Read more →SPRCSciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery
SciSparc Ltd. has announced the launch of an innovative initiative focused on 3D protein modeling using quantum computing technology. This project aims to enhance drug discovery by providing unprecedented accuracy in predicting protein structures and their interactions with ligands. The company plans to form a dedicated research team and collaborate with experts in quantum computing and structural biology. A new wholly owned subsidiary will manage this initiative, which targets applications in rare and neurological diseases.
Read more →SPRCSciSparc: AutoMax’s Shareholders Approve Merger with SciSparc
SciSparc Ltd. announced that AutoMax Motors' shareholders approved the merger with SciSparc. This strategic move will allow SciSparc to acquire 100% of AutoMax's share capital, enhancing its operations in the automotive sector. The merger aligns with SciSparc's long-term strategy to diversify and capitalize on the electric vehicle market in Israel.
Read more →SPRCSciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel
SciSparc Ltd. has received shareholder approval for its merger with AutoMax Motors Ltd., a leading vehicle importer in Israel. This strategic move aims to diversify SciSparc's operations into the automotive sector, particularly in the electric vehicle market. The merger is expected to enhance shareholder value, although it remains subject to customary closing conditions and approvals.
Read more →SPRCSciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
SciSparc Ltd., in collaboration with Clearmind Medicine Inc., has published an international patent application for a novel combination therapy targeting obesity and metabolic syndrome. The therapy combines Clearmind's MEAI and SciSparc's PEA, leveraging their combined anti-inflammatory and neuroprotective properties. This milestone marks significant progress in their partnership, which has already led to the filing of 13 patent families. Despite the optimistic outlook, the potential benefits are accompanied by risks inherent in forward-looking statements regarding future results.
Read more →SPRCSciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc., resulting in the filing of an international patent application for a novel combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). This innovative therapy utilizes MEAI and PEA, aiming to address significant health issues that currently have limited treatment options. The partnership highlights the companies' commitment to developing therapies that could provide effective solutions to global health challenges. The filing adds to multiple existing patents stemming from their collaboration, reflecting ongoing research efforts to expand therapeutic avenues.
Read more →SPRCSciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC
SciSparc Ltd. announced that the SEC has declared effective its Form F-4 registration statement for a proposed merger with AutoMax Motors Ltd. The merger, originally agreed upon in April 2024, will see SciSparc acquire AutoMax, which operates in the electric vehicle sector in Israel. Shareholder meetings are scheduled for late August 2025 to vote on the merger, marking significant progress. The transaction is expected to offer new opportunities for both companies and enhance SciSparc’s shareholder value.
Read more →SPRCSCISPARC LTD. AND ITS SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 U.S. DOLLARS IN THOUSANDS INDEX Page Report of Independent Registered Public Accounting Firm (PCAOB ID 1281) F-2 - F-3 Consolid
SciSparc Ltd. reported its consolidated financial statements as of December 31, 2024, revealing significant losses and ongoing fiscal challenges. The company's liquidity position raises substantial doubt regarding its ability to continue as a going concern. Despite presenting the financial statements in accordance with international standards, the management acknowledged the potential risks associated with their financial future. The report indicates that the company has incurred losses since its inception and anticipates further losses ahead.
Read more →SPRCSciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
SciSparc Ltd. has confirmed its compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum bid price of $1.00 for 10 consecutive business days. This compliance resolution, communicated on July 18, 2025, indicates that the previous bid price deficiency issue is now closed. SciSparc is a clinical-stage pharmaceutical company focused on developing therapies related to rare central nervous system disorders, including autism and Alzheimer's disease.
Read more →SPRCTHE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF SCISPARC LTD. As Adopted on
The article provides a detailed outline of the Amended and Restated Articles of Association for SciSparc Ltd. as adopted on June 26, 2025. It includes definitions of key terms such as 'Affiliate,' 'Board of Directors,' and 'Shareholder,' and outlines the company's objectives, procedures for share management, and conditions for shareholder meetings. The document serves as a legal framework for the company's governance under the Israeli Companies Law.
Read more →SPRCSciSparc Announces 1-for-21 Reverse Share Split
SciSparc Ltd. announced a 1-for-21 reverse share split, effective July 3, 2025. This decision was approved by shareholders at the Annual General Meeting on October 23, 2024. The move is intended to reduce the number of issued shares from approximately 11.2 million to about 534,600, although it will not change current ownership percentages. Trading will continue under the ticker SPRC, and shareholders need not take any action for the exchange process.
Read more →SPRCSciSparc Announces 1-for-21 Reverse Share Split Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held Tel Aviv, Israel
SciSparc Ltd. (Nasdaq: SPRC) announced a 1-for-21 reverse share split effective July 3, 2025, aiming to reduce the number of outstanding shares from 11,225,751 to approximately 534,600. This move was approved by shareholders during the Annual General Meeting held on October 23, 2024. The reverse split will not alter any shareholder's percentage of ownership, as fractional shares will be managed accordingly. The company, which focuses on therapies for central nervous system disorders, also maintains its trading symbol on the Nasdaq Capital Market.
Read more →SPRCin this Report of Foreign Private Issuer on Form 6-K. Information has been prepared based on these preliminary estimates, and the final amounts recorded may differ materially from the information presented. The unaudited
SciSparc Ltd. has announced its partnership with AutoMax Motors Ltd. through a merger agreement. The deal includes multiple addendums and aims to integrate AutoMax as a wholly-owned subsidiary, potentially boosting SciSparc's market position. An unaudited pro forma financial statement has been prepared to reflect the merger's impact, although there are provisions indicating that final amounts may vary and rely on future financial assessments. The overall tone of the announcement is optimistic regarding the growth opportunities presented by this merger.
Read more →SPRCSciSparc Announces Publication of Japanese Patent Application
SciSparc Ltd. announced the publication of a Japanese divisional patent for a new pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA). This combination aims to enhance pain and fever relief while reducing side effects compared to traditional paracetamol use. SciSparc's CEO highlighted the innovation as a safer option for patients of all ages, potentially minimizing risks such as liver damage. The company is focused on developing cannabinoid-based therapies and has multiple drug development programs underway.
Read more →SPRCSciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that resulted in a published European patent for a combination therapy targeting cocaine addiction. This therapy utilizes Clearmind's 5-methoxy-2-aminoindane (MEAI) along with SciSparc's Palmitoylethanolamide. Preclinical trials showed that MEAI significantly reduces cravings for cocaine without affecting responses to natural rewards. This development adds to the companies' ongoing intellectual property efforts in treating addiction.
Read more →SPRCSciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
SciSparc Ltd. announced a collaboration with Clearmind Medicine Inc., resulting in the filing of an international patent application for a new treatment targeting anorexia, bulimia, and other eating disorders. This novel approach combines 3-Methylmethcathinone with SciSparc's Palmitoylethanolamide, aiming to tackle the complex factors underlying these disorders. The announcement highlights the urgency of addressing the rising prevalence of eating disorders globally. The potential impact of this treatment underscores promise, amidst the risks associated with developing new therapies in this sensitive area.
Read more →SPRCSciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
SciSparc Ltd. has published a patent application in South Korea, in collaboration with Clearmind Medicine Inc., for a treatment that combines MEAI and PEA aimed at cocaine addiction. The patent is grounded in preclinical trial findings that demonstrated MEAI significantly reduced drug-seeking behavior without affecting responses to natural rewards. This development enhances the ongoing partnership between the two companies and adds to their growing portfolio of intellectual property related to their innovative treatments.
Read more →SPRCSciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
SciSparc Ltd. has finalized an agreement to sell its majority stake in MitoCareX to N2OFF for $700,000, allowing SciSparc to exchange its remaining shares for stock in N2OFF. The sale aims to optimize SciSparc's asset portfolio while providing N2OFF ownership of MitoCareX as a subsidiary. The transaction includes potential future financial benefits based on milestone achievements and proceeds from financing. However, completion is contingent on shareholder approval and other customary conditions.
Read more →SPRCSciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles
SciSparc Ltd. has announced a $2 million loan to AutoMax Motors Ltd. to support its business expansion into direct imports of JAC electric vehicles. This funding is in addition to earlier bridge loans totaling $4.25 million. The loan terms include an 8% annual interest rate, with monthly repayments of $50,000. Furthermore, a merger agreement has been signed between SciSparc and AutoMax, which is set to enhance SciSparc's operations in the automotive sector, pending practical approval from shareholders.
Read more →SPRCSciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
SciSparc Ltd. has announced a favorable settlement regarding a lawsuit filed against its former directors. The settlement includes a $411,000 cash payment and a full release from all claims related to the lawsuit, allowing the company to retain exclusive rights to its intellectual property. Additionally, a licensing agreement that was in dispute has been terminated, further clarifying SciSparc's ownership of its core technologies. This resolution enables the company to concentrate on its development programs in cannabinoid pharmaceuticals.
Read more →SPRCSciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
SciSparc Ltd. announced a significant advancement in its collaboration with Clearmind Medicine, leading to the publication of a patent application in Mexico. This patent focuses on a novel combination therapy designed to treat various binge behaviors, integrating MDMA with N-Acylethanolamines. The collaboration reflects ongoing efforts to develop innovative treatment options for mental health issues. The companies have filed a total of 13 related patents, demonstrating a robust approach to intellectual property in this area.
Read more →SPRCSciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
SciSparc Ltd. has received a 180-day extension from Nasdaq to comply with the minimum bid price rule, allowing until July 14, 2025, for compliance. Despite failing to meet the $1.00 bid price requirement in the first period, the company still fulfills other listing requirements. The extension means there is no immediate impact on the trading or listing of SciSparc's shares on Nasdaq. The company has indicated intentions to rectify the deficiency possibly through a reverse stock split if necessary.
Read more →SPRCSciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
SciSparc Ltd. has announced that AutoMax Motors received its first shipment of electric vehicles from JAC Motors, marking a significant milestone in its import operations. This partnership is aimed at addressing the rising demand for electric vehicles in Israel. SciSparc has provided financial backing to AutoMax, reinforcing their merger agreement designed to expand into the automotive sector. However, the merger remains contingent on various approvals and closing conditions.
Read more →SPRCSciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
SciSparc Ltd. has announced that its joint venture, MitoCareX Bio, is expanding its research into pancreatic cancer following positive initial in-vitro results. The company aims to build on prior successes in drug discovery related to the mitochondrial SLC25 protein family. MitoCareX is also developing a predictive AI model to optimize their drug discovery processes. This strategic expansion addresses the significant unmet medical need in treating pancreatic cancer, known for its aggressive nature and low survival rate.
Read more →SPRCSciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. to develop a novel treatment for binge behavior using a psychedelic combination therapy. A European patent application has been published for this therapy, which includes MEAI and N-Acylethanolamines. The collaboration has already resulted in numerous patent filings, emphasizing its commitment to advancing therapeutic options in the mental health space. Both companies focus on leveraging psychedelic-derived compounds to address significant under-treated health issues.
Read more →SPRCSciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
SciSparc Ltd. has announced the renewal of its approval from the Israeli Medical Cannabis Agency to continue its clinical trial for SCI-210, targeting children with autism spectrum disorder. This proprietary treatment combines cannabidiol and CannAmide™. The trial, conducted at Soroka University Medical Center, will assess the efficacy and safety of SCI-210 compared to standard CBD treatment over 20 weeks. The company plans for commercialization in Israel and aims to expand internationally, pending regulatory approvals.
Read more →SPRCSciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
SciSparc Ltd. has announced that its partner, AutoMax Motors, received its first shipment of vehicles from JAC Motors following regulatory approvals for direct importation. This development allows AutoMax to initiate marketing and sales operations in Israel. Furthermore, the upcoming merger between SciSparc and AutoMax, aimed at enhancing SciSparc's presence in the automotive sector, is contingent upon shareholder approval and other closing conditions, introducing certain risks to the transaction's completion.
Read more →SPRCSciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
SciSparc Ltd. (Nasdaq: SPRC) has announced an amendment to its non-binding LOI to spin off its advanced pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. to Miza III Ventures Inc. This transaction, valued at approximately US$11.6 million, aims to enhance shareholder value, with a definitive agreement expected by March 31, 2025. Following the closing, SciSparc would hold a controlling interest in Miza, which operates in both pharmaceutical and supplement sectors.
Read more →SPRCin this Report of Foreign Private Issuer on Form 6-K . 4 Information has been prepared based on these preliminary estimates, and the final amounts recorded may differ materially from the information presented. The unaudi
SciSparc Ltd. has entered into a merger agreement with AutoMax Motors Ltd., with the deal subject to conditions detailed in the agreement and its addendums. Pro forma financial statements have been prepared to reflect the expected effects of the merger based on historical data as of mid-2024. The estimated merger consideration is approximately $2.33 million, reliant on fluctuating share prices. However, the presented financial information remains preliminary and could be adjusted as final valuations are completed.
Read more →SPRCSCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4
SCISPARC LTD. announced its interim consolidated financial statements for the period ending June 30, 2024, revealing a notable increase in operating losses and a significant decline in cash reserves. The company reported a total comprehensive loss of $3,679,000, with an accumulated deficit reaching $72,133,000. While there was a slight increase in share capital, overall financial health appears to be deteriorating based on these findings. The firm continues to face challenges, reflected in higher research and development expenses and liabilities.
Read more →SPRCSciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
SciSparc Ltd. announced that the FDA has approved its investigational new drug application to proceed with Phase IIb clinical trials for its candidate SCI-110 in adults with Tourette Syndrome. This trial aims to assess the efficacy, safety, and tolerability of the drug, following promising results from an earlier Phase IIa trial. The study will be conducted at three prestigious medical centers, underscoring the significance of this research in addressing management challenges associated with Tourette Syndrome. The company's CEO emphasized the unmet medical need for more effective therapies in this area.
Read more →SPRCto the Company's Report of Foreign Private Issuer on Form 6-K, furnished to the U.S. Securities and Exchange Commission on
SciSparc Ltd. has announced the rescheduling of its Annual General Meeting to October 22, 2024, where shareholders will vote on several proposals. A key agenda item is the proposed Reverse Share Split, aimed at restoring compliance with Nasdaq's minimum bid price requirement. The company has faced challenges, prompting the Board to support a more flexible split ratio of up to 1:30. The outcome of this meeting is crucial for the company's future trading attractiveness and compliance status.
Read more →SPRCSciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
SciSparc Ltd. has signed a non-binding letter of intent to sell its stake in MitoCareX Bio Ltd., aimed at enhancing shareholder value. The initial transaction involves selling 27% of its shares for $700,000, while the remaining stake could yield an additional $8 million based on future milestones. This move indicates a significant increase in MitoCareX's valuation since SciSparc's initial investment. However, the agreement is non-binding and must be finalized through negotiations.
Read more →SPRCSciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
SciSparc Ltd. has received FDA approval to initiate a Phase IIb clinical trial for its drug candidate SCI-110 aimed at treating Tourette Syndrome. The trial will be conducted in collaboration with three renowned medical institutions, including Yale School of Medicine. The main objectives are to evaluate the efficacy, safety, and tolerability of SCI-110 in adults diagnosed with Tourette Syndrome. This development builds on positive preliminary results from earlier clinical trials, reinforcing the company's commitment to providing innovative treatments for central nervous system disorders.
Read more →SPRCSciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
SciSparc Ltd. has submitted an Investigational New Drug application to the FDA for a Phase IIb clinical trial of its drug candidate SCI-110, aimed at treating Tourette Syndrome. The trial will take place at prestigious institutions, including the Yale Child Study Center and Hannover Medical School. Approval has been secured from relevant health authorities, and the trial aims to assess the drug's efficacy and safety in adult patients between 18 and 65 years old. This marks a crucial step in the development of new therapeutic options for Tourette Syndrome.
Read more →SPRCSciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
SciSparc Ltd. and Clearmind Medicine Inc. have announced the publication of an international patent application for a new Ibogaine combination therapy aimed at improving mental health and addiction treatments. This collaboration highlights their ongoing research efforts to combine psychedelic molecules with N-acylethanolamines to enhance therapeutic benefits. With a total of thirteen patents filed related to this partnership, both companies aim to address significant under-treated mental health issues. However, there are forward-looking statements suggesting inherent risks and uncertainties surrounding the anticipated outcomes of these innovative therapies.
Read more →SPRCSciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
SciSparc Ltd. has advanced an additional $1.85 million loan to AutoMax Motors Ltd., following a direct import agreement between AutoMax and the Chinese vehicle manufacturer JAC Motors. This brings the total amount loaned under the bridge loan agreement to $4.25 million. The financial arrangement includes a fixed charge security interest on AutoMax's subsidiary's shares. The direct import agreement is expected to bolster AutoMax's market position in the automotive sector.
Read more →SPRCSciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
SciSparc Ltd. has announced the publication of an international patent application for a combination treatment involving MDMA and N-Acylethanolamines, in collaboration with Clearmind Medicine Inc. This innovative therapeutic approach aims to enhance the safety and efficacy of treatments for mental health and addiction disorders. Thirteen patents related to this collaboration have been filed, suggesting a strong commitment to addressing regulatory concerns surrounding MDMA safety. The partnership represents a significant advancement in the development of novel psychedelic-derived therapeutics.
Read more →SPRCSciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
SciSparc Ltd. has announced a collaboration with Clearmind Medicine, resulting in the publication of a patent application for a novel ketamine-based combination treatment. This innovative therapy combines SciSparc's Palmitoylethanolamide (PEA) with Clearmind's psychedelic molecule MEAI, aimed at addressing mental health disorders and addictions. The collaboration has led to the filing of thirteen patents, underlining their strong research focus. FDA-approved ketamine treatments require strict administration guidelines due to potential side effects, emphasizing the importance of SciSparc's goal to enhance treatment efficacy while minimizing adverse reactions.
Read more →SPRCSciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
SciSparc Ltd. has entered into an Exclusive Patent License Agreement with Polyrizon Ltd. for the out-licensing of its SCI-160 program aimed at treating pain. The agreement could provide SciSparc with consideration valued at $6 million, including $3 million in securities and milestone fees contingent on development success. The SCI-160 therapy combines cannabinoids and N-acylethanolamines, showing promising pre-clinical results in pain management with fewer side effects than traditional opioids. This strategic move may enhance SciSparc's portfolio in the competitive biopharma landscape.
Read more →SPRCSciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
SciSparc Ltd. announced the submission of an Investigational New Drug application to the U.S. FDA for its phase IIb clinical trial of SCI-110, aimed at treating Tourette Syndrome. The trial will take place at renowned institutions including the Yale Child Study Center and Hannover Medical School. It intends to assess the efficacy, safety, and tolerability of SCI-110 in adults with TS, using standard clinical measures. The company has secured necessary approvals for the trial, reflecting confidence in this innovative treatment approach.
Read more →SPRCSciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
SciSparc Ltd. has announced the appointment of Professor Nir Peled to the scientific advisory board of its venture, MitoCareX Bio Ltd. Peled brings a wealth of expertise in thoracic oncology, with notable contributions to cancer research and treatment. His involvement is expected to bolster MitoCareX's efforts in developing innovative therapeutics targeting the mitochondrial SLC25 protein family for cancer. Additionally, MitoCareX has previously demonstrated successful results using their drug discovery platform to identify potential anti-cancer treatments.
Read more →SPRCSciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
SciSparc Ltd. has announced the enrollment and dosing of the first five patients in its clinical trial for SCI-210, aimed at treating autism spectrum disorder (ASD). Conducted at the Soroka Medical Center in Israel, the trial involves 60 participants aged 5 to 18 years and will assess SCI-210's efficacy compared to standard CBD therapy. The company plans to commercialize SCI-210 initially in Israel, pending regulatory approvals. The trial's design includes metrics to evaluate improvement in ASD symptoms, aligning with the company’s mission to enhance patient outcomes.
Read more →SPRCSciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
SciSparc Ltd. has signed an Exclusive Patent License Agreement with Polyrizon Ltd. for its SCI-160 pain therapy program. This agreement may yield up to $6 million in value, including $3 million in share consideration and additional milestone fees. SCI-160 is a proprietary synthetic treatment combining cannabinoids and N-acylethanolamines, which has shown promising efficacy in pain management with minimal side effects. The deal allows SciSparc to potentially benefit from royalties as Polyrizon develops the therapy without requiring further capital investment from SciSparc.
Read more →SPRCSciSparc Updates Regarding the Status of the AutoMax Merger
SciSparc Ltd. (Nasdaq: SPRC) has announced progress regarding its merger with AutoMax Motors Ltd., following approval from the Jerusalem District Court to convene special shareholder meetings. This approval allows AutoMax's shareholders to vote on the merger. Additionally, an addendum to the merger agreement has extended the deadline for completing the merger until November 30, 2024. SciSparc is actively engaged in developing therapies for central nervous system disorders.
Read more →SPRCSciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
SciSparc Ltd. announced the publication of a new study showcasing the effectiveness of a combination treatment using Palmitoylethanolamide and Clearmind's MEAI for weight loss and combating obesity. The study revealed that the treatment reduced fat mass while preserving lean mass, improved glucose metabolism, and increased energy expenditure in mice. This collaboration aims to develop innovative therapies for obesity and metabolic syndrome, demonstrating promising results from rigorous scientific research.
Read more →SPRCSciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
SciSparc Ltd. has announced that its venture, MitoCareX Bio Ltd., has confirmed the significant potential role of the SLC25 protein in treating Non-Small Cell Lung Cancer (NSCLC) through genetic manipulation and advanced 3D modeling. The NSCLC market is projected to reach approximately $59.77 billion by 2030, driving innovation in therapeutic approaches. MitoCareX has utilized its proprietary MITOLINE algorithm to screen small molecules for potential anti-cancer applications and is working to develop a predictive AI model to discover new therapies targeting the SLC25 protein.
Read more →SPRCSciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
SciSparc Ltd. has announced a non-binding letter of intent with an undisclosed biotechnology company for the out-licensing of its SCI-160 program, which is aimed at treating pain. The agreement could result in total payments of approximately $6 million, combining shares and potential milestone payments. SCI-160 is an innovative cannabinoid formulation, showing effective analgesic properties without significant side effects. This move allows SciSparc to concentrate on its primary drug development programs targeting Alzheimer’s disease and other conditions.
Read more →SPRCSciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
SciSparc Ltd. has announced the submission of a U.S. patent application for a proprietary composition aimed at treating metabolic syndrome and obesity, developed in collaboration with Clearmind Medicine. This composition combines Palmitoylethanolamide (PEA) with Clearmind’s MEAI compound. The market for obesity treatments, projected to grow significantly in the coming years, presents potential growth opportunities for the company. This patent application is part of a broader collaboration involving twelve other patents targeting various health issues.
Read more →SPRCSciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
SciSparc Ltd. announced that it received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement. The company has been granted a 180-day period to regain compliance, during which its shares will continue to trade. If compliance is not achieved, additional options may be available to avoid delisting. The company focuses on developing cannabinoid-based pharmaceuticals for various disorders.
Read more →SPRCSciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
SciSparc Ltd. announced it signed a non-binding letter of intent to spin off its advanced clinical stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. to Miza III Ventures Inc. This agreement values SciSparc's assets at approximately $11.6 million and aims to allow SciSparc to maintain a controlling interest in the resulting entity. The spin-off aligns with the company's strategy to create shareholder value and includes a range of drug development programs targeting disorders such as Tourette syndrome and Alzheimer’s disease.
Read more →SPRCSciSparc Secures Strategic Advantage with Grant of European Patent
SciSparc Ltd. has secured a European patent for its innovative compositions and methods designed to enhance the efficacy of antimicrobials while reducing side effects. This grant complements an existing U.S. patent and significantly strengthens the company’s patent portfolio. The focus of this patent is on combining antibiotics with cannabinoids to prevent microbial biofilm formation and related diseases, addressing the growing public health challenge of antimicrobial resistance. The expansion of its intellectual property rights marks a strategic advantage for SciSparc in the global pharmaceutical landscape.
Read more →SPRCAutomax Motors Ltd. Consolidated Financial Statements as for
Automax Motors Ltd. has released its audited consolidated financial statements for the years ending December 31, 2023, and 2022. The auditors have expressed an opinion that the statements fairly represent the financial position of the company in accordance with International Financial Reporting Standards (IFRS). However, the company faces legal issues related to an indictment and signs of asset impairment, both of which present potential risks to its operations. Despite these challenges, management has outlined steps to maintain financial stability and meet obligations in the near future.
Read more →SPRCSciSparc to Acquire AutoMax
SciSparc Ltd. announced its agreement to acquire AutoMax Motors Ltd., leading to the establishment of a wholly-owned subsidiary that will merge with AutoMax. This acquisition aims to maximize shareholder value, with SciSparc shareholders retaining approximately 50.01% ownership in the combined company. The transaction requires several regulatory approvals and shareholder consents before it can be finalized. SciSparc has committed to retain $4.25 million in net cash following the acquisition.
Read more →SPRCExecution Copy AGREEMENT AND PLAN OF MERGER among SCISPARC LTD. , an Israeli limited company; SCISPARC MERGER SUB LTD. , an Israeli limited company; and AUTOMAX MOTORS LTD. , an Israeli limited company Dated as of
SciSparc Ltd. has entered into an Agreement and Plan of Merger with AutoMax Motors Ltd., marking a significant strategic move for both companies. The merger will result in AutoMax becoming a wholly-owned subsidiary of SciSparc, aiming to enhance SciSparc's market position. All involved parties have agreed that the merger is in their best interests and will be subject to regulatory and shareholder approvals. The agreement outlines the terms and conditions necessary for the merger to proceed.
Read more →SPRCSciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
SciSparc Ltd. announced a new international patent application in collaboration with Clearmind Medicine Inc. for a compound aimed at preventing and treating depression. The application covers the combination of Clearmind's MEAI compound with SciSparc's CannAmide™, enhancing their efforts in addressing major mental health issues. This patent application is part of a broader collaboration which has previously led to nine other applications targeting various mental health and addiction disorders. The global market for depression and anxiety treatments presents significant growth opportunities, projected to reach USD 41.83 billion by 2034.
Read more →SPRCSciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
SciSparc Ltd. announced a significant development by its venture, MitoCareX Bio, which has utilized advanced computational tools to virtually screen millions of small molecules for potential anti-cancer therapies. Confirmatory tests have shown biological activity in several identified molecules. Furthermore, MitoCareX aims to enhance its drug discovery process by creating a predictive AI model, aimed at uncovering new anti-cancer scaffolds. This progress marks a promising step toward novel cancer treatment options.
Read more →SPRCSciSparc Granted Another Patent, Strengthening its Core Technology in Canada
SciSparc Ltd. has been granted a patent by the Canadian Intellectual Property Office for its innovative technology involving cannabinoids and n-acylethanolamines. This patent aims to improve the safety of cannabinoid treatments while preserving their therapeutic effects. The CEO highlighted the significance of this patent in reinforcing the company’s intellectual property rights, contributing to the development of treatments for central nervous system disorders. With this patent, SciSparc continues to build its value and technological capabilities in the cannabis space.
Read more →SPRCSciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
SciSparc Ltd. has announced the successful dosing of the first patient in its clinical trial for SCI-210, aimed at treating Autism Spectrum Disorder in pediatric patients. This milestone marks the shift from preparatory work to active treatment evaluation. The trial will assess the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy, involving a rigorous 20-week study with data collected from 60 children. SciSparc focuses on cannabinoid-based therapeutics, and this achievement positions them closer to addressing the needs of families affected by ASD.
Read more →SPRCSciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
SciSparc Ltd. announced that its venture MitoCareX Bio has made significant strides in anti-cancer drug discovery. Utilizing advanced computational screening and in-vitro testing, MitoCareX identified multiple small molecules with anti-cancer potential. The venture is also focused on developing a predictive AI model to enhance the efficiency of future drug discovery efforts. This announcement highlights SciSparc's commitment to innovative therapies targeting the mitochondrial SLC25 protein family.
Read more →SPRCSciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
SciSparc Ltd. has announced the enrollment of its first patient in a clinical trial aimed at evaluating the efficacy and safety of its drug SCI-210 in treating children with autism spectrum disorder (ASD). This double-blind study will involve 60 subjects aged 5 to 18 and is designed to compare SCI-210's effects against standard CBD treatment. The trial will last for 20 weeks, and the company plans to eventually market SCI-210 in Israel and other countries upon obtaining regulatory approvals. The initiative is supported by the National Autism Research Center, marking a significant step in addressing the unmet needs in ASD treatment.
Read more →SPRCSciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
SciSparc Ltd. has successfully completed the granting process for its core-technology patent in several European countries, complementing existing patents in regions such as the U.S. and Australia. This patent covers innovative combinations of cannabinoids and n-acylethanolamines aimed at enhancing therapeutic effects while minimizing side effects. With approval in key countries like Germany, France, and the UK, this advancement supports SciSparc's technology portfolio focused on treating central nervous system disorders.
Read more →SPRCSciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
SciSparc Ltd. has received approval from the Canadian Intellectual Property Office for a patent related to its technology aimed at reducing opioid use in pain management. The technology combines opioids with n-acylethanolamines to potentially enhance therapeutic effects and lower doses, thereby reducing addiction risks. The approval marks a significant step for SciSparc in gaining global recognition for its innovations. However, the ongoing opioid crisis poses challenges, and the company's future success is contingent on further validation of its technology.
Read more →SPRCSciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
SciSparc Ltd. has announced the successful manufacturing and delivery of its SCI-210 treatment for Autism Spectrum Disorder (ASD), enabling the commencement of a clinical trial at the Soroka Medical Center. This trial will enroll 60 pediatric patients and assess the safety, tolerability, and efficacy of SCI-210 in comparison to CBD monotherapy. The trial will last for 20 weeks and includes several rigorous primary efficacy endpoints. SciSparc's CEO expressed excitement about reaching this milestone and hopes it leads to commercialization in Israel.
Read more →SPRCSciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
SciSparc Ltd. announced a partnership with Clearmind Medicine Inc., resulting in the filing of three new international patent applications for MDMA, ibogaine, and ketamine compounds. These patents include novel compositions combined with palmitoylethanolamide, a key ingredient from SciSparc's CannAmide™. Additionally, Clearmind has filed a total of eight patent applications focused on various therapeutic combinations aimed at treating alcohol use disorder, cocaine addiction, and obesity. This collaboration underscores the companies' commitment to addressing major under-treated mental health problems.
Read more →SPRCSciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
SciSparc Ltd. announced a collaboration with Clearmind Medicine Inc. to file three new patent applications under the international Patent Cooperation Treaty. These applications pertain to novel combinations of psychedelic compounds and CannAmide™, a proprietary ingredient of SciSparc. The CEO of SciSparc emphasized the added value that CannAmide™ can provide when paired with these therapeutic compounds. This expansion reflects the company's ongoing commitment to enhance its intellectual property and focus on the treatment of mental health disorders.
Read more →SPRCSciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
SciSparc Ltd. has announced the initiation of patient recruitment for a clinical trial of its proprietary product, SCI-210, designed to treat children with autism spectrum disorder (ASD) at Soroka Medical Center in Israel. The trial will involve 60 subjects aged 5 to 18 over 20 weeks, comparing the effectiveness of SCI-210 with standard CBD treatments. The company aims to commercialize SCI-210 in Israel pending regulatory approvals. This trial marks a significant step in addressing ASD symptoms and aligns with SciSparc's mission to enhance human health through innovative therapies.
Read more →SPRCSciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
SciSparc Ltd. has entered a $20 million standby equity purchase agreement with YA II PN, Ltd. This agreement allows SciSparc to sell shares over a three-year period, which provides a financial boost for working capital and corporate needs. The shares will be sold at a slight discount to the market average, contingent on SEC registration. The funds will enable the company to continue its focus on developing cannabinoid-based therapies for various central nervous system disorders.
Read more →SPRCSciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
SciSparc Ltd. has announced a bridge loan agreement of $1.4 million with a prominent vehicle importer in Israel, facilitating its plans to acquire the company. This loan, which bears interest at 7% per annum, is intended to support the finalization of the acquisition. The agreement implies that SciSparc will establish a wholly-owned subsidiary that will merge with the target company, leading to shareholders of SciSparc owning approximately 50.01% of the resulting entity. The company has communicated its commitment to following through with the acquisition as previously implied by a non-binding letter of intent.
Read more →SPRCSciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
SciSparc Ltd. reflects positively on its successful 2023 collaboration with Clearmind Medicine Inc., which resulted in the filing of six provisional patent applications for innovative psychedelic therapies. These patents aim to combine various psychedelics with SciSparc's active ingredient, PEA, to improve treatment options for mental health disorders. The collaboration signifies a commitment from both companies to develop safer and more effective therapeutic solutions, enhancing their intellectual property portfolios. Moving forward, any assets generated from this partnership will be jointly owned by both companies.
Read more →SPRCSciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
SciSparc Ltd. announced that its joint venture, MitoCareX Bio, has reached its second milestone in drug development, allowing for further investment from SciSparc. The company developed diverse small-molecule screening platforms aimed at finding potential anti-cancer drug candidates. With this achievement, SciSparc is positioned to increase its ownership in MitoCareX Bio to 50.1%. The progress highlights the potential for developing innovative cancer treatments.
Read more →SPRCSciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
SciSparc Ltd. has provided updates on its recent non-binding letter of intent to acquire a prominent vehicle importer in Israel. The deal aims for SciSparc shareholders to gain a majority stake in the new combined entity, increasing from 20% to approximately 50.01%. The success of the acquisition will depend on due diligence, binding agreements, and necessary regulatory approvals. The target company reported substantial revenues of over $52 million in the first half of 2023, framing the acquisition as a potentially strategic enhancement for SciSparc.
Read more →SPRCSciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
SciSparc Ltd. announced successful results from a pre-clinical trial of its proprietary Combination Treatment, which uses CannAmide™ and MEAI to target obesity and related metabolic disorders. Conducted by Professor Joseph Tam from The Hebrew University, the trial indicated increased metabolic activity, reduced appetite, and enhanced fat oxidation in treated animals. The trial demonstrated that the Combination Treatment was safe, as all test subjects maintained viability. SciSparc's CEO expressed optimism regarding the treatment's potential efficacy in addressing obesity-related health challenges.
Read more →SPRCSciSparc Adopts Limited Duration Shareholder Rights Plan
SciSparc Ltd. has adopted a limited-duration shareholder rights plan to protect the interests of its shareholders amidst significant fluctuations in its stock price. This Rights Plan, effective immediately, allows shareholders to purchase additional ordinary shares under certain conditions, thus discouraging hostile takeovers. CEO Oz Adler highlighted positive results from the company's metabolic disorder program, reinforcing their commitment to shareholder value. The plan will remain in effect for up to one year, encouraging potential buyers to negotiate directly with the company.
Read more →SPRCSciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
SciSparc Ltd. has signed a non-binding letter of intent to merge with a leading vehicle importer in Israel. This merger is set to result in the Target Company becoming a wholly-owned subsidiary of SciSparc. Subsequently, SciSparc plans to transfer its pharmaceutical activities to a new legal entity, potentially allowing for dividend distributions to shareholders. The merger is subject to various approvals and due diligence, but could enhance revenue and shareholder returns if successful.
Read more →SPRCSciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
SciSparc Ltd. announced positive results from its Phase IIa trial of SCI-110, which aims to alleviate agitation in elderly Alzheimer's patients. Conducted at the Israeli Alzheimer’s Medical Center, the trial demonstrated significant safety and tolerability, with no severe side effects. The treatment led to a 23% reduction in agitation symptoms, marking a promising advancement in Alzheimer's care. Given the limitations of existing treatments, SCI-110 presents a potential breakthrough solution for this urgent health concern.
Read more →SPRCSciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
SciSparc Ltd. has announced the initiation of a Phase IIb clinical trial for its drug candidate, SCI-110, aimed at treating Tourette Syndrome. The trial will take place across multiple sites in the USA, Israel, and Germany, and has secured necessary regulatory approvals. Previous clinical trials showed promising results, with significant tic reduction in patients. While the company is optimistic about the drug's efficacy, future outcomes remain uncertain due to various inherent risks.
Read more →SPRCSciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
SciSparc Ltd. announced the acceptance of its patent application for a Combination of Opioids and N-Acylethanolamines to treat pain. The patent, granted by IP Australia, reflects the company's commitment to developing innovative pain management therapies. SciSparc's CEO emphasized the importance of this patent in recognizing the effectiveness and safety of their technologies, which aim to reduce opioid use while maintaining pain relief. The global opioid market is projected to grow, which may benefit SciSparc's initiatives in this area.
Read more →SPRCSciSparc Granted Patent for its Core Technology From the Australian Patent Office
SciSparc Ltd. has been granted a new patent by the Australian Patent Office for its innovative technology related to cannabinoids and N-acylethanolamines. This patent aligns with the Company's objectives of improving the safety and efficacy of cannabinoid-based therapies. It adds to the existing patents previously granted in key markets such as the U.S., Europe, and Japan. SciSparc is focusing on developing therapies for central nervous system disorders, leveraging this patent to enhance its drug development programs.
Read more →SPRCCORPORATE PRESENTATION Nasdaq: SPRC October 2023 This presentation of SciSparc Ltd . (the " Company " or " SciSparc " ) contains " forward - looking statements " within the meaning of the Private Securities Litigation Re
SciSparc Ltd. (Ticker: SPRC) has provided an overview of its current research and development activities, highlighting three advanced clinical trials and the successful results of its Phase IIa trial for Alzheimer's Disease. The company recently raised $6.3 million and reported revenue generation from its consumer supplement line, Wellution. Ongoing collaborations and patent applications further underscore SciSparc's commitment to addressing various neurological and psychiatric conditions.
Read more →SPRCSCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4
SCISPARC Ltd. released its interim consolidated financial statements for the six months ending June 30, 2023, revealing a substantial increase in operating losses. The company reported revenues of $1,972,000, yet experienced a comprehensive loss of $2,932,000. Additionally, cash reserves saw a dramatic decline from $12,945,000 at the end of 2022 to $2,081,000. These figures indicate considerable challenges ahead for the company's financial stability.
Read more →SPRCSciSparc Ltd. Announces Closing of $5.026 Million Private Placement
SciSparc Ltd. has announced the successful closing of a private placement that generated approximately $5.026 million in gross cash proceeds. The placement involved the issuance of 1,930,108 units, which consist of Pre-Funded Warrants that are immediately exercisable. The company plans to file registration statements with the SEC for the resale of the shares underlying these warrants. This move is part of SciSparc's ongoing efforts to enhance its portfolio of cannabinoid pharmaceuticals.
Read more →SPRCSciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
SciSparc Ltd. has announced a private placement agreement to raise approximately $5.026 million through the sale of units consisting of Pre-Funded Warrants. The transaction will close around October 13, 2023, pending customary closing conditions. This initiative is aimed at enhancing the company's financial resources to advance its clinical-stage pharmaceutical programs focusing on cannabinoid-based treatments. The securities involved are exempt from federal registration requirements, adding a layer of regulatory complexity.
Read more →SPRCSciSparc Granted European Patent for its Core Technology
SciSparc Ltd. has been granted a European patent for its innovative approach to cannabinoid-based therapies, confirming its unique technology in the cannabis space. This patent, which supports previously granted patents in the U.S., Japan, and Australia, pertains to enhancing the therapeutic effects of cannabinoids while minimizing side effects. The company's CEO emphasized ongoing efforts to expand its intellectual property and the potential of cannabinoid medicines. SciSparc is focused on developing treatments for various disorders, further bolstering its position in the pharmaceutical market.
Read more →SPRCSciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
SciSparc Ltd. has announced the initiation of a pivotal clinical trial for its drug candidate, SCI-210, aimed at treating Autism Spectrum Disorder (ASD). The trial, conducted at Soroka University Medical Center, will involve 60 children aged 5-18 and will assess the safety and efficacy of SCI-210 compared to CBD monotherapy. The study is designed in collaboration with Israel's National Autism Research Center, emphasizing a commitment to scientific rigor and patient safety. SCI-210 combines CBD with Palmitoylethanolamide, potentially improving treatment outcomes for children with ASD.
Read more →SPRCSciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
SciSparc Ltd. announced the implementation of a 1-for-26 reverse share split, which will take effect after market close on September 27, 2023. The company’s Ordinary Shares will begin trading on a post-split basis on September 28, 2023. This move follows approval from shareholders at the Annual Meeting held on August 18, 2023, and aims to consolidate the company's share structure without adjusting the authorized share capital. The number of issued and outstanding Ordinary Shares will decrease from approximately 13.5 million to about 521,090.
Read more →SPRCSciSparc Announces 1-for-26 Reverse Share Split
SciSparc Ltd. has announced a reverse share split at a ratio of 1-for-26, which will take effect on September 28, 2023. This decision follows the approval from shareholders during the Annual Meeting held on August 18, 2023. The company aims to maintain its trading symbol ‘SPRC’ on the Nasdaq Capital Market following the split, while fractional shares will be rounded to the nearest whole share. The split is a part of a broader strategy to enhance the company's market position and shareholder value.
Read more →SPRCSciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
SciSparc Ltd. has engaged Rosario Capital to explore potential strategic transaction opportunities aimed at maximizing shareholder value. This decision follows the company's previous announcement in June 2022 to consider strategic transactions. Rosario Capital will assess various options, including partnerships and licensing agreements. Meanwhile, SciSparc will continue with its existing development programs in cannabinoid pharmaceuticals.
Read more →SPRCSciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
SciSparc Ltd. has announced the initiation of a Phase IIb clinical trial for its proprietary drug SCI-110, intended for the treatment of Tourette Syndrome. The trial will take place at leading medical centers, including Tel Aviv Sourasky Medical Center, Yale Child Study Center, and Hannover Medical School. The study is based on positive results from an earlier trial and aims to evaluate the drug's efficacy by measuring tic severity in adult patients. With regulatory approvals secured, the company is optimistic about the potential commercialization of SCI-110.
Read more →SPRCSciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
SciSparc Ltd. has successfully closed a public offering, raising approximately $1.3 million, which will be utilized for working capital. The offering comprised 6,500,000 ordinary shares priced at $0.20 each. Additionally, the company granted Aegis Capital Corp. the option to purchase up to 975,000 additional shares to cover any over-allotments. Should this option be fully exercised, total proceeds could reach approximately $1.5 million.
Read more →SPRCSciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
SciSparc Ltd. has announced the pricing of a public offering expected to raise approximately $1.3 million. The offering consists of 6,500,000 ordinary shares priced at $0.20 each, with additional proceeds possible through overallotment options. The net proceeds are intended for working capital purposes. This offering is scheduled to close on August 14, 2023, subject to customary conditions. Aegis Capital Corp. is managing the offering.
Read more →SPRCSciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
SciSparc Ltd. has announced a proposed underwritten public offering intended to raise approximately $1.3 million to bolster its working capital. The offering, which is contingent upon market conditions, will be managed by Aegis Capital Corp., which may also have the option to purchase additional shares. The public offering is made under an effective shelf registration statement, and interested investors are encouraged to review the relevant prospectus once available. With a focus on cannabinoid pharmaceuticals, the company is engaged in several drug development programs targeting various conditions.
Read more →SPRCSciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
SciSparc Ltd. has filed a provisional patent application in collaboration with Clearmind Medicine Inc. for the treatment of dyskinesia and dystonia using the psychedelic molecule 3-MMC and Palmitoylethanolamide. This patent aims to address movement disorders associated with conditions like Tourette Syndrome and Parkinson's disease. The new application adds to SciSparc's already strong intellectual property portfolio, as the company continues to pursue innovative therapies for unmet medical needs. The filing demonstrates the ongoing commitment to developing effective treatments in the field of movement abnormalities.
Read more →SPRCSciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
SciSparc Ltd. has received approval from the Israeli Medical Cannabis Agency to commence a clinical trial for its drug SCI-210, aimed at treating children with autism spectrum disorder. This proprietary formulation combines cannabidiol and CannAmide and is positioned to address the significant gap in effective treatments for ASD. The trial will take place at Soroka University Medical Center, assessing the drug's safety and efficacy over a 20-week period. The company hopes successful outcomes will facilitate commercialization in Israel and beyond.
Read more →SPRCSciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
SciSparc Ltd. has received approval from the Federal Institute for Drugs and Medical Devices in Germany for a Phase IIb clinical trial of its drug candidate SCI-110 to treat Tourette Syndrome. The trial will be conducted at three prestigious centers, including Hannover Medical School in Germany and Yale Child Study Center in the USA. This trial aims to assess the efficacy and safety of SCI-110, which is considered a potentially transformative therapy for patients with this neurological disorder. However, the approval is contingent upon the submission of additional stability and release information within 90 days.
Read more →SPRCSciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
SciSparc Ltd. announced that it has obtained Institutional Review Board (IRB) approval for its Phase IIb clinical trial of SCI-110, aimed at treating Tourette Syndrome in adults. This trial will assess the drug's efficacy, safety, and tolerability through a randomized, double-blind, placebo-controlled methodology. The upcoming study is supported by positive findings from a prior Phase IIa trial, which demonstrated a notable decrease in tic symptoms. The trial will take place at multiple centers, including Yale University, Hannover Medical School, and Tel Aviv Sourasky Medical Center.
Read more →SPRCSciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
SciSparc Ltd. has announced a research agreement with Clearmind Medicine Inc. to evaluate a proprietary combination treatment for obesity and metabolic syndrome. This collaboration, in partnership with the Hebrew University of Jerusalem, will assess the effects of SciSparc's Palmitoylethanolamide and Clearmind’s MEAI. Prior studies indicated that MEAI can promote weight loss and improve metabolic health metrics in rodents. This initiative represents SciSparc's commitment to developing innovative therapies addressing significant health challenges.
Read more →SPRCSciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
SciSparc Ltd. announced an exclusive licensing agreement with its subsidiary, SciSparc Nutraceuticals, to sell CannAmide™ on the Amazon marketplace in Canada. CannAmide™, a novel palmitoylethanolamide (PEA) formulation, is designed to alleviate chronic pain and inflammation. The agreement is for a term of 12 months and entails a revenue-sharing model. This partnership aims to enhance SciSparc Nutraceuticals' market presence and product offerings while focusing on PEA's therapeutic benefits.
Read more →SPRCSciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
SciSparc Ltd. announced positive results from its Phase IIa trial of SCI-110 for Alzheimer's patients experiencing agitation. The trial showed that SCI-110 was safe and well-tolerated, with patients demonstrating significant improvements in agitation symptoms. Notably, 13 out of 15 patients exhibited a reduction in agitation measures, showing the potential of SCI-110 as a viable treatment option. The trial results suggest that this new therapy could enhance the quality of life for Alzheimer's patients in need of effective agitation management.
Read more →SPRCSciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
SciSparc Ltd. has appointed Yaki Baranes as its new Vice President of Strategy and Business Development in a move to drive its corporate restructuring and unlock value for shareholders. With a robust background in business strategy and consulting, Baranes will help identify new business opportunities for the specialty clinical-stage pharmaceutical company. This change aligns with SciSparc's ongoing efforts to explore diverse investment avenues and optimize its portfolio, which includes cannabinoid-based therapies for various medical conditions.
Read more →SPRCscisparc ltd. Ordinary Shares (no par value) At-The-Market Issuance Sales Agreement
SciSparc Ltd. announced an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. to issue and sell its ordinary shares, up to a maximum offering of approximately $1.73 million. Aegis will act as the exclusive sales agent for this initiative. The shares will be issued pursuant to a previously filed registration statement effective with the SEC. The company retains control over the terms of placements, including timing and pricing.
Read more →SPRCSciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program
SciSparc Ltd. announced that its joint venture MitoCareX Bio has successfully developed MITOLINE™, an algorithm facilitating the creation of reliable 3D models of human mitochondrial carriers. These models are aimed at advancing drug discovery for cancers and life-threatening conditions. The algorithm addresses challenges posed by the limited availability of solved 3D structures of these proteins, potentially aiding the development of more effective cancer therapies. The project aims to enhance the modeling and understanding of mitochondrial transporters involved in various malignancies.
Read more →SPRCSciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
SciSparc Ltd. has successfully completed treatment for the last patient enrolled in its Phase IIa clinical trial of SCI-110 for Alzheimer's Disease and agitation. The interim results previously announced indicated that the trial met its primary endpoints regarding safety and efficacy. Six out of eight patients demonstrated a reduction in agitation, and the medication was well tolerated without significant adverse effects. Full trial results are expected in the coming weeks, but there are inherent risks related to future performance and outcomes.
Read more →SPRCSciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
SciSparc Ltd. announced the filing of a provisional patent application in collaboration with Clearmind Medicine Inc. to protect a novel psychedelic-based treatment for depression. This new application is part of a broader effort that includes three other patents aimed at treating alcohol use disorder, cocaine addiction, and obesity. Additionally, six more patents were filed concerning combinations with various psychedelic compounds. This move is expected to bolster SciSparc's portfolio in cannabinoid pharmaceuticals.
Read more →SPRCSciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
SciSparc Ltd. has received final approval from the Tel Aviv Sourasky Medical Center to initiate its Phase IIb clinical trial for SCI-110, aimed at treating Tourette Syndrome. This trial, a randomized, double-blind study, will evaluate the safety, efficacy, and tolerability of SCI-110 in adult patients. The trial will also be conducted at multiple sites, including Yale Child Study Center and Hannover Medical School, pending necessary approvals. Company officials express optimism about the treatment's potential to offer safer and more effective solutions for patients with Tourette Syndrome.
Read more →SPRCSciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
SciSparc Ltd. has finalized the sale of a 49% stake in its subsidiary, SciSparc Nutraceuticals Inc., which owns the Wellution brand, for about $3 million. This agreement includes cash payments and a share exchange with Jeffs' Brands Holdings Inc., which will also provide management services for Wellution. The brand has a strong presence on Amazon with numerous top-selling hemp-based products. Following the transaction, SciSparc retains a controlling interest in its subsidiary, holding approximately 51%. However, there are risks associated with the subsidiary's future performance and management dependency.
Read more →SPRCSciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million Upon the closing which occurred on
SciSparc Ltd. has finalized the sale of a 49% interest in its subsidiary, SciSparc Nutraceuticals Inc., which owns the Wellution brand. The transaction was valued at an adjusted price of approximately $3 million, following an increase from the initial $2.5 million. Alongside this sale, a consulting agreement has been established with Jeffs' Brands for management services. However, the deal includes risks associated with deferred payments and regulatory compliance regarding share offerings.
Read more →SPRCSciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
SciSparc Ltd. has received approval from the Israeli Ministry of Health to conduct a Phase IIb clinical trial for its drug SCI-110, aimed at treating Tourette Syndrome in adults. The first clinical site approved for this trial is the Tel Aviv Sourasky Medical Center, with plans to expand to Yale University and Hannover Medical School, pending further regulatory approvals. The trial will assess the efficacy, safety, and tolerability of SCI-110 through a randomized, double-blind, placebo-controlled study format, using the Yale Global Tic Severity Scale as a key measure.
Read more →SPRCSciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
SciSparc Ltd. has successfully manufactured clinical batches of its proprietary drug candidate SCI-110, which will be used in an upcoming Phase IIb trial for Tourette Syndrome. This trial is set to evaluate the efficacy and safety of the drug in adult patients. The company has gained necessary approvals from ethics committees in Germany and Israel and is preparing to submit a request to Yale University's Institutional Review Board. The outcome of this trial could significantly impact the treatment options available for Tourette Syndrome patients.
Read more →SPRCSciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
SciSparc Ltd. has entered an agreement with Tikun Olam Cannbit Pharmaceuticals to supply CBD-rich cannabis oil for its upcoming clinical trial on children with autism spectrum disorder (ASD). This trial, which has received approval from the Israeli Ministry of Health and is set to be led by Prof. Gal Meiri at Soroka University Medical Center, will assess the safety, tolerability, and efficacy of the proprietary SCI-210 treatment. SciSparc's focus on developing cannabinoid-based therapies aims to address significant treatment gaps in pediatric populations.
Read more →SPRCSciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
SciSparc Ltd. has signed an agreement to sell a 49% interest in its subsidiary, SciSparc Nutraceuticals Inc., to Jeffs' Brands Ltd. for $2.5 million. The transaction may increase in value by approximately $300,000 due to inventory adjustments. Following the sale, which must meet certain conditions, SciSparc will retain a 51% stake in the subsidiary and will benefit from management services provided by Jeffs' Brands. The collaboration aims to strengthen the marketing and sale of Wellution's hemp-based products on Amazon.
Read more →SPRCSciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. to develop unique combinations of psychedelic-derived compounds. Clearmind has filed three provisional patent applications with the USPTO for combinations including MDMA, Ibogaine, and Ketamine in conjunction with SciSparc's CannAmide™. This partnership also includes multiple other patent applications targeting treatments for alcohol use disorder, cocaine addiction, and obesity. Any resulting assets from this collaboration will belong to both companies.
Read more →SPRCSciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
SciSparc Ltd. announced that its joint venture, MitoCareX Bio, has achieved its first milestone by establishing a cloud-based computing infrastructure, facilitating future expansion into machine learning for drug discovery. This milestone enables the investigation of mitochondrial carriers critical for cell viability, with potential applications in treating cancer and rare diseases. Following this achievement, SciSparc will increase its investment in MitoCareX Bio by $400,000, raising its ownership stake. MitoCareX Bio is also enhancing its drug discovery platform and is involved in virtual screening activities.
Read more →SPRCThe following risk factors update and supplement, and should be read together with, the risk factors previously provided under "Risk Factors" in Part I, Item 3.D. in SciSparc Ltd.'s Annual Report on Form 20-F for the yea
SciSparc Ltd. has updated its risk factors related to business operations, corporate restructuring, and eCommerce activities. The company notes the uncertainty associated with entering definitive agreements following letters of intent, and the potential volatility of investments. Additionally, the restructuring plan to transfer pharmaceutical activities to a subsidiary may not go as planned, exposing the company to various risks without certain anticipated benefits. The challenges in integrating eCommerce operations further highlight operational uncertainties and potential financial impacts.
Read more →SPRCSciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. to file three provisional patent applications with the USPTO. These patents focus on novel psychedelic-based combinations using SciSparc's CannAmide™ and other psychedelics for treating various mental health disorders. The partnership aims to maximize therapeutic effects and address under-treated mental health problems. Synergy from their combined intellectual property could lead to innovative treatments, though future results remain uncertain due to inherent risks in clinical trials.
Read more →SPRCSciSparc Announces Corporate Restructuring plan SciSparc will examine the possibility of a public listing for its pharmaceutical activity while retaining a controlling interest
SciSparc Ltd. announced a corporate restructuring plan aimed at transferring its pharmaceutical activities to a new wholly owned subsidiary. This initiative may include exploring the potential for publicly listing the subsidiary while retaining control of its operations. The company intends to leverage this reorganization to continue its focus on developing therapies for central nervous system disorders and may seek other investment opportunities. The announcement includes forward-looking statements indicating that results could differ from expectations.
Read more →SPRCSciSparc Announces Corporate Restructuring plan
SciSparc Ltd. has announced a corporate restructuring plan to transfer its pharmaceutical activities to a wholly owned subsidiary. The company is considering a public listing for this subsidiary while retaining a controlling interest. This restructuring aims to boost operational efficiency and allow for exploration of new investment opportunities across various sectors. However, the plan carries uncertainties related to its implementation and potential market reactions.
Read more →SPRCSciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares
SciSparc Ltd. has announced that its board intends to investigate concerns regarding potential illegal short sales of its ordinary shares, which it believes have negatively impacted its stock price. The company plans to explore various alternatives to tackle this issue and is following the lead of other public companies in the sector. SciSparc aims to engage specialized professionals to analyze trading patterns related to its shares, indicating a determined approach to ensure fair trading practices.
Read more →SPRCSciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
SciSparc Ltd. has received approval from the Soroka University Medical Center to conduct a clinical trial of its drug SCI-210 in children diagnosed with autism spectrum disorder (ASD). The trial, which follows previous approvals from Israeli health authorities, aims to assess the efficacy and safety of SCI-210 compared to CBD monotherapy. The study will include 60 participants and will employ a randomized, double-blind, placebo-controlled design over 20 weeks, focusing on several primary efficacy endpoints related to behavioral improvements in children.
Read more →SPRCSciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
SciSparc Ltd. announced positive results from pre-clinical studies regarding MEAI, a drug candidate from Clearmind Medicine Inc., aimed at treating cocaine addiction. The studies demonstrated that MEAI may effectively reduce cravings without disrupting natural reward mechanisms. Ongoing collaboration between the two companies has led to a provisional patent application focused on utilizing MEAI in cocaine addiction treatment. The research conducted by Professor Gal Yadid indicates the potential for MEAI to maintain natural rewards while addressing addiction.
Read more →SPRCSciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
SciSparc Ltd. has signed an agreement with Soroka Medical Center to conduct a clinical trial for its proprietary treatment SCI-210 in patients with autism spectrum disorder (ASD). The trial has already received approvals from the Ethics Committee and the Israeli Ministry of Health. It will assess the efficacy and safety of SCI-210 compared to CBD monotherapy. This study aims to establish new treatment solutions for ASD and enhance SciSparc's clinical program portfolio.
Read more →SPRCSciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
SciSparc Ltd. has announced initial positive results from a collaboration with Clearmind Medicine regarding the treatment of obesity using MEAI, a novel psychedelic molecule. The pre-clinical study demonstrated that MEAI led to significant weight loss and improved metabolic health in rodents. This treatment could address the obesity epidemic, which affects over 1 billion people globally, and represents a potential multibillion-dollar market. The results highlight the possible benefits of combining SciSparc's CannAmide with Clearmind's MEAI.
Read more →SPRCSCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4
INTERIM CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4 Consolidated Statements of Changes in Equity (Deficit) 5-7 Consolidated Statements of Cash Flows 8-10 Notes
Read more →SPRCSciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
TEL AVIV, Israel, Dec. 14, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has ent
Read more →SPRCSciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the centr
Read more →SPRCSciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), reported the receipt of a formal n
Read more →SPRCSciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line
The new line of products will be in the fields of quality health and lifestyle products such as nutritional and dietary supplements for various purposes TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical c
Read more →SPRCSciSparc Gains Competitive Edge with Additional U.S. Patent Granted
This patent extends protection, adding to six other U.S. patents already granted TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of th
Read more →SPRCSciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
Meets primary endpoints- SCI-110 administration was found to be safe at all tested doses SCI-110 treatment was also found to reduce agitation - 75% of patients did not need to use additional medication to control agitation and 75% of patients experienced increased appetite SciS
Read more →SPRCSciSparc: Wellution™ Signs an Agreement with Logistics Facilities in New Jersey to Supports its Expansion to Additional e-Commerce Platforms
Agreement is expected to optimize handling and shipment processes and reduce direct sales costs TEL AVIV, Israel, Nov. 01, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the develop
Read more →SPRCSciSparc: Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days
Since launch the new product has had approximately 117% ROI TEL AVIV, Israel, Oct. 28, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders o
Read more →SPRCSciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com Marketplace TEL AVIV, Israel, Sept. 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutic
Read more →SPRCSciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes
TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that Clearmind
Read more →SPRCSciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com Marketplace TEL AVIV, Israel, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceut
Read more →SPRCSciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to tre
Read more →SPRCScisparc Announces the Full Exercise of Pre-Funded Warrants
The pre-funded warrants were issued as part of the $10 million private placement from June 2022 TEL AVIV, Israel, Aug. 19, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the developme
Read more →SPRCSciSparc will Deposit $1 million in Escrow for its Intention to Enter Into an Agreement to Acquire American Food Supplements and Cosmetics Brand
The Company has signed an escrow agreement following the signing of a non-binding letter of intent and will be deposit a $1.0 million as an initial intention to enter into a definitive acquisition agreement TEL AVIV, Israel, Aug. 18, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasda
Read more →SPRCSciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal
The Letter of Intent contemplates the purchasing of a brand, trademark and Amazon.com seller account, a management agreement, a U.S. distribution agreement and an option to expand to new territories TEL AVIV, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)
Read more →SPRCSciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan TEL AVIV, Israel, Aug. 12, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development
Read more →SPRCAugust 11, 2022 Dear SciSparc Ltd. Shareholders: We cordially invite you to attend the Annual General Meeting of Shareholders of SciSparc Ltd. (the “ Meeting ”), to be held on Thursday, September�
Dear SciSparc Ltd. Shareholders: We cordially invite you to attend the Annual General Meeting of Shareholders of SciSparc Ltd. (the Meeting ), to be held on Thursday, September 15, 2022 at 3:00 p.m. (Israel time), at the Company's offices, at 20 Raul Wallenberg Street, Tower A T
Read more →SPRCSciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD TEL AVIV, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmace
Read more →SPRCSciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage
Read more →SPRCSciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome
TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has started
Read more →SPRCSciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility
The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies
Read more →SPRCSciSparc Board of Directors to Promote Buyback Program of up to $1 Million
TEL AVIV, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced its board
Read more →SPRCLETTER AGREEMENT
Bank Name: Bank Leumi Le Israel B.M. Branch Name: Leumitech Business Center 864 Branch Address: 15 Hamenofim St., Herzilia Account No: 33530048 SWIFT: LUMIILITXXX IBAN: IL530108640000033530048 [Signature Page Follows] the parties hereto have caused this Letter Agreement t
Read more →SPRCSciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it ha
Read more →SPRCSciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment TEL AVIV, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutica
Read more →SPRCSciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins
JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat di
Read more →SPRCSciSparc's Board of Directors Provides Strategic Decision
TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that the Co
Read more →SPRCSciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc.
TEL AVIV, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that initia
Read more →SPRCSciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction
No dedicated treatment currently available for cocaine addiction TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous
Read more →SPRCSciSparc Ltd. Announces Closing of $10 Million Private Placement Priced At-the-Market
TEL AVIV, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today closed its previously
Read more →SPRCSciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology TEL AVIV, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the dev
Read more →SPRCSciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
TEL AVIV, Israel, May 27, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it ente
Read more →SPRCSciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in Germany and Israel TEL AVIV, Israel, May 26, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing o
Read more →SPRCSciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment
Pre-clinical trials based on the proprietary combination demonstrate significant suppressive effect on alcohol consumption TEL AVIV, Israel, May 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the developm
Read more →SPRCSciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors
Preclinical study results demonstrated the combination of SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption TEL AVIV, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical compa
Read more →SPRCSciSparc Files Annual Report for Year Ended December 31, 2021 and Provides Corporate Update
TEL AVIV, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced that it has
Read more →SPRCSciSparc Announces Closing of New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
TEL AVIV, Israel, March 31, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced completio
Read more →SPRCSciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial Results demonstrated that combining SciSparc's CannAmide with Clearmind's MEAI has the potential to reduce alcohol consumption
SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial demonstrated that combining SciSparc's CannAmide with Clearmind's MEAI has the potential to reduce alcohol consumption AVIV, Israel, March 17, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a spec
Read more →SPRCSciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases Research builds on studies with support from global experts in the field of small molecule drugs and gene editing
SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases Research builds on studies with support from global experts in the field of small molecule drugs and gene editing TEL AVIV, Israel, March 10, 2022 /PRNewswire/ -- SciSparc Ltd.
Read more →SPRCSciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals TEL AVIV, Israel, March 8, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat di
Read more →SPRCCORPORATE PRESENTATION Nasdaq: SPRC February 2022 This presentation of SciSparc Ltd . (the " Company " ) contains " forward - looking statements " within the meaning of the Private Securities Litigation Reform Act and ot
CORPORATE PRESENTATION Nasdaq: SPRC February 2022 This presentation of SciSparc Ltd . (the " Company " ) contains " forward - looking statements " within the meaning of the Private Securities Litigation Reform Act and other securities laws . Words such as " expects, " " anticipa
Read more →SPRCSciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110 The Dual-Site Study Will Be Conducted at the Hannover Medical School in Germany , and Israel's
Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110 The Dual-Site Study Will Be Conducted at the Hannover Medical School in Germany, and Israel's Tel-Aviv Sourasky Medical Center TEL AVIV, Israel, January 18, 2022 /PRNew
Read more →SPRCSciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease The clinical trial will be conducted at The Israeli Alzheimer's Medical Center and will evaluate the safety, tolerab
SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease The clinical trial will be conducted at The Israeli Alzheimer's Medical Center and will evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer'
Read more →SPRCSciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders Patent Extends Protection for its Novel Compounds and Methods Already granted in Australia and Japan
SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders Patent Extends Protection for its Novel Compounds and Methods Already granted in Australia and Japan TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC),
Read more →SPRCSciSparc Provides Updates Upon Conclusion of 2021
SciSparc Provides Updates Upon Conclusion of 2021 TEL AVIV, Israel, Dec. 29, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Co
Read more →SPRCSciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today
SciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today TEL AVIV, Israel, Dec. 22, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ:SPRC) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the centr
Read more →SPRCSciSparc Announces Approval of Uplisting to The Nasdaq Capital Market
SciSparc Announces Approval of Uplisting to The Nasdaq Capital Market TEL AVIV, Israel, Dec. 20, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCF) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nerv
Read more →SPRCOther than as expressly set forth above, this Amendment does not, and does not purport to, amend, update or restate the information in any other item of the Original Form 6-K, or reflect any events that have occurred aft
INTERIM CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4 Consolidated Statements of Changes in Equity (Deficit) 5-7 Consolidated Statements of Cash Flows 8-10 Notes
Read more →SPRCSCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4
INTERIM CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4 Consolidated Statements of Changes in Equity (Deficit) 5-7 Consolidated Statements of Cash Flows 8-10 Notes
Read more →SPRCSciSparc Announces Completion of Corporate Rebranding and Launch of New Website
SciSparc Announces Completion of Corporate Rebranding and Launch of New Website TEL AVIV, Israel, Aug. 4, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today an
Read more →SPRCSciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome SciSparc intends to evaluate the efficacy, safety and tolerability of its Proprietary Cannabinoid-Based Treatment- SCI-110
SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome SciSparc intends to evaluate the efficacy, safety and tolerability of its Proprietary Cannabinoid-Based Treatment- SCI-110 TEL AVIV, Israel, July 26, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCY
Read more →SPRCSciSparc to Commence Phase IIa Clinical Trial of SCI-110 for the Treatment of Alzheimer's Disease and Agitation Trial will be conducted at the Israeli Medical Center for Alzheimer's and will evaluate the safety, tolerabi
SciSparc to Commence Phase IIa Clinical Trial of SCI-110 for the Treatment of Alzheimer's Disease and Agitation TEL AVIV, Israel, July 7, 2021 /PRNewswire/ -- SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: SPRCY) a specialty, clinical-stage pharmaceutical
Read more →SPRCSCISPARC
SPECIAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that the Special General Meeting of the shareholders (the "Meeting") of SciSparc Ltd. (the "Company") will be held at the Company's offices, 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel, on Friday, Ju
Read more →SPRCSciSparc Ltd. Announces $8.15 Million Private Placement
SciSparc Ltd. Announces $8.15 Million Private Placement TEL AVIV, Israel, March 1, 2021 /PRNewswire/ -- SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-bas
Read more →SPRCSciSparc Corporate Presentation February 2021 Safe Harbor Statement This presentation of SciSparc Ltd. (the " Company " ) contains " forward - looking statements " within the meaning of the Private Securities Litigation
SciSparc Corporate Presentation February 2021 Safe Harbor Statement This presentation of SciSparc Ltd. (the " Company " ) contains " forward - looking statements " within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as " expec
Read more →SPRCSciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer's Patients Using the Company's Proprietary Cannabinoid-Based Treatment The Israeli Medical Center for Alzheimer's will evaluate the safety, tolerability and eff
SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer's Patients Using the Company's Proprietary Cannabinoid-Based Treatment The Israeli Medical Center for Alzheimer's will evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer's disease and
Read more →SPRCSciSparc Announces Rebranding and Business Updates
SciSparc Announces Rebranding and TEL AVIV, Israel, February 11, 2021- SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments (formerly known as Therapix Biosciences Ltd.), today announced se
Read more →SPRCSciSparc Engages Procaps for Development and Production of CannAmide and its SCI-110 Product Candidate The companies will work together on next phase of development following successful phase IIa clinical study for Toure
Engages Procaps for Development and Production of CannAmide and its SCI-110 Product Candidate companies will work together on next phase of development following successful phase IIa clinical study for Tourette Syndrome in 2018 and preparations for CannAmide commercialization i
Read more →SPRCSciSparc Initiates Commercial Production of its CannAmide Pills The Anti-Inflammatory, Chronic Pain Treatment Is Expected to Be Distributed In Pharmacies Across Canada
Commercial Production of its CannAmide Pills The Anti-Inflammatory, Chronic Pain Treatment Is Expected to Be Distributed In Pharmacies Across Canada February 9, 2021 - SciSparc Ltd.(formerly known as Therapix Biosciences Ltd.) (OTCQB: TRPXY), a specialty, clinical-stage pharma
Read more →SPRCTherapix Biosciences Announces Name Change to SciSparc Ltd.
Therapix Biosciences Announces Name Change to SciSparc Ltd. AVIV, Israel, Jan. 28, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has chan
Read more →SPRCTHERAPIX
GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that the Special General Meeting of the shareholders (the "Meeting") of Therapix Biosciences Ltd. (the "Company") will be held at the offices of Meitar Law Offices, 16 Abba Hillel Silver Rd. Ramat Gan 5250608, Israel, on M
Read more →SPRCTherapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada Therapix's TheraPEA product has all required Canadian approvals for distribution
Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada Therapix's TheraPEA product has all required Canadian approvals for distribution TEL AVIV, Israel, January 5, 2021- Therapix Biosciences Ltd. (OTCQB: TR
Read more →SPRCTherapix Biosciences Announces Upgrade to OTCQB Venture Market
Therapix Biosciences Announces Upgrade to OTCQB Venture Market TEL AVIV, Israel, Dec. 8, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-
Read more →SPRCTherapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain "In the era of America's deadly opioid crisis, cutting-edge pain therapeutics like THX
Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain "In the era of America's deadly opioid crisis, cutting-edge pain therapeutics like THX-160 possess the potential to be a new and effective trea
Read more →SPRCTherapix Biosciences Announces Pricing of $4.2 Million Offering
Biosciences Announces Pricing of $4.2 Million Offering AVIV, Israel, Nov. 19, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (OTC Pink: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based trea
Read more →SPRCTHERAPIX BIOSCIENCES LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2020 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehen
THERAPIX BIOSCIENCES INTERIM CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4 Consolidated Statements of Changes in Equity (Deficit) 5-7 Consolidated Statements of
Read more →SPRCDeveloping cannabinoid based pharmaceuticals Corporate Presentation September 2020 Saf e Harbo r Statement This presentation of Therapix Biosciences Ltd . (the "Company") contains "forward - looking statements" within th
Developing cannabinoid based pharmaceuticals Corporate Presentation September 2020 Saf e Harbo r Statement This presentation of Therapix Biosciences Ltd . (the "Company") contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act a
Read more →SPRCTherapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court
Therapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court Israel, July 9, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the developm
Read more →SPRCTherapix Biosciences Raises $2.6 Million in Private Placement TEL-AVIV, Israel
Therapix Biosciences Raises $2.6 Million in Private Placement TEL-AVIV, Israel, June 29, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-
Read more →SPRCSHARE TRANSFER AGREEMENT THIS SHARE TRANSFER AGREEMENT (the " Agreement ") is made and entered into as of
SHARE TRANSFER AGREEMENT (the "Agreement") is made and entered into as of May 15, 2020, by and among, Capital Point Ltd., a public company traded on TASE, registered under the laws of the State of Israel and a shareholder of the Company (the "Seller"), Therapix Biosciences, Ltd
Read more →SPRCTherapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors
Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors Israel, May 7, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of can
Read more →SPRCNasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements
Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements TEL AVIV, Israel, April 28, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on t
Read more →SPRCTherapix Biosciences Announces Appointment of New CEO Mr. Gilad Bar-Lev appointed CEO effective as of
Therapix Biosciences Announces Appointment Mr. Gilad Bar-Lev appointed CEO effective as of May 6, 2020 TEL AVIV, Israel, April 22, 2020 /PRNewswire/ - Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the d
Read more →SPRCTherapix Biosciences Ltd. Signs Securities Purchase Agreement
Therapix Biosciences Ltd. Signs Securities Purchase Agreement TEL AVIV, Israel, March 19, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatmen
Read more →SPRCTherapix Biosciences Ltd. Receives Nasdaq Notification Regarding Minimum Bid Requirements
Therapix Biosciences Ltd. Receives Nasdaq Notification Regarding Minimum Bid Requirements TEL AVIV, Israel, Feb. 27, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-bas
Read more →SPRCNasdaq Hearings Panel Grants Therapix
Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements TEL AVIV, Israel, Feb. 6, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of
Read more →SPRCTherapix Biosciences Announces
Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering Tel-Aviv, Israel, Dec. 4, 2019 /PRNewswire/ - Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development
Read more →SPRCTherapix Biosciences Announces the Continued Development of THX-210 ( RESPECTRUM ) Cannabinoids Based Treatment for Autism Spectrum Disorder
Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder TEL AVIV, Israel, Dec. 2, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ: TRPX), a specialty, cli
Read more →SPRCTherapix Biosciences Announces Receipt of Notice of Delisting from Nasdaq and Intention to Appeal
Therapix Biosciences Announces Receipt of Notice of Delisting from Nasdaq and Intention to Appeal AVIV, Israel, November 20, 2019 --Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the develo
Read more →SPRCTherapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd.
Therapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd. Parties to Move Towards Definitive Agreements to Merge Therapix With the Rapidly Expanding Hemp CBD Company Heavenly Rx is Led by Paul Norman -- Former Kellogg's President of North America Hea
Read more →SPRCTherapix Biosciences Announces Positive
Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program Study meets its primary endpoint TEL AVIV, Israel, Nov. 13, 2019 /PRNewswire/ - Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq
Read more →SPRCTherapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger
Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger AVIV, Israel, Nov. 7, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company f
Read more →SPRCTherapix Biosciences Announces Positive Data From Recent Pre-Clinical Study for New Drug Candidate THX-210
Therapix Biosciences Announces Positive Data From Recent Pre-Clinical Study for New Drug Candidate THX-210 AVIV, Israel, Oct. 15, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of can
Read more →SPRCTherapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.
Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp. TEL AVIV, Israel, Oct. 10, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on
Read more →SPRCNasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement
Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement TEL AVIV, Israel, Aug. 27, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on t
Read more →SPRCTherapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide ), a Non-Opiate Based Pain Management Supplement TEL AVIV, Israel, July 31 2019 /PRNewswire Therapix Biosciences Ltd. ( Therapix or
Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide ), a Non-Opiate Based Pain Management Supplement TEL AVIV, Israel, July 31 2019 /PRNewswire Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ: TRPX), a specialty, clinical-st
Read more →SPRCBiosciences Signs LOI to Merge With Destiny Biosciences Global Corp.
Biosciences Signs LOI to Merge With Destiny Biosciences Global Corp. in a for Stock Transaction Valuing Therapix at US$48 Million TEL AVIV, Israel, July 23, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or "the Company") (NASDAQ: TRPX), a specialty, clinical-stage
Read more →SPRCTherapix Biosciences Announces First Quarter 2019 Condensed Financial Data
Therapix Biosciences Announces First Quarter 2019 Condensed Financial Data TEL AVIV, Israel, July 4, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or "the Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of
Read more →SPRCTherapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program
Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program TEL AVIV, Israel, June 18, 2019 /PRNewswire/ - Therapix Biosciences Ltd. ("Therapix" or "the Company") (Nasdaq: TRPX), a specialty, clinical-stage pha
Read more →SPRCBiosciences Issues Shareholder Update Letter
Biosciences Issues Shareholder Update Letter AVIV, Israel, May 29, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today
Read more →SPRCTherapix Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Non-Compliance
Therapix Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Non-Compliance TEL AVIV, Israel, May 23, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical
Read more →SPRCTherapix Biosciences Announces Pricing of $2.25 Million Registered Direct Offering Tel-Aviv, Israel
Biosciences Announces Pricing $2.25 Million Registered Direct Offering Tel-Aviv, Israel, March 28, 2019 /PRNewswire/ - Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of can
Read more →SPRCTherapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor
Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor AVIV, Israel, March 19, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannab
Read more →SPRCTHE CANNABINOIDS OF THE FUTURE
THE CANNABINOIDS OF THE FUTURE D ISCLAIMER This presentation of Therapix Biosciences Ltd. (the "Company") contains "forward - looking statements" within the meaning of the P rivate Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates,
Read more →SPRCGENERAL MEETING OF SHAREHOLDERS
GENERAL MEETING OF SHAREHOLDERS is hereby given that the Annual General Meeting of the shareholders (the "Meeting") of Therapix Biosciences Ltd. (the "Company") will be held at the offices of the Company at 4 Ariel Sharon Street, HaShahar Tower, 16th Floor, Givatayim 5320047,
Read more →SPRCTherapix Biosciences Terminates FSD Acquisition
Therapix Biosciences Terminates FSD Acquisition TEL AVIV, Israel, December 21, 2018 /PRNewsire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treat
Read more →SPRCTherapix Biosciences Provides Update Regarding FSD Acquisition
Therapix Biosciences Provides Update Regarding FSD AVIV, Israel, Dec. 11, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments,
Read more →SPRCInvestors | Therapix Biosciences Therapix Biosciences Reports Third Quarter 2018 Financial Results and Provides Business Update
| Therapix Biosciences Biosciences Reports Third 2018 Financial Results and AVIV, Israel, Dec. 3, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of can
Read more →SPRCTherapix Biosciences Clarifies Terms of Recently Issued Convertible Debenture
Therapix Biosciences Clarifies Terms of Recently Issued Convertible Debenture AVIV, Israel, Nov. 29, 2018 /PRNewsire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of can
Read more →SPRCManagement's Discussion and Analysis of Financial Condition and Results of Operations The following presentation of management's discussion and analysis of financial condition and results of operations for the six month
Discussion and Analysis of Financial Condition and Results of Operations The following presentation of management's discussion and analysis of financial condition and results of operations for the six month periods ended June 30, 2018 and 2017 should be read in conjunction wi
Read more →SPRCTherapix Biosciences Issues $1,500,000 Convertible Debenture
Biosciences Issues $1,500,000 Convertible Debenture AVIV, Israel, Nov. 26, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments,
Read more →SPRCTherapix Biosciences Signs Binding LOI to be Acquired by FSD Pharma for $48 Million,
Therapix Biosciences Signs Binding LOI to be Acquired by FSD Pharma for $48 Million, to Create Medical Cannabis Industry Innovator AVIV, Israel, Oct. 24, 2018 /PRNewswire/ -- Biosciences Ltd. ("Therapix") (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusi
Read more →SPRCTHERAPIX BIOSCIENCES LTD. Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update
THERAPIX BIOSCIENCES LTD. Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update AVIV, Israel, August 20, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the
Read more →SPRCTherapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update AVIV, Israel, May 31, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based
Read more →SPRCTherapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update - Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT
Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT - AVIV, Israel, November 9, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmac
Read more →SPRCNOTICE OF ANNUAL GENERAL MEETING Exhibit 1 THERAPIX BIOSCIENCES LTD. NOTICE OF 2017
THERAPIX BIOSCIENCES 2017 ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that the Annual and a Special General Meeting of the shareholders (the "Meeting") of Therapix Biosciences Ltd. (the "Company") will be held at the offices of the Company at 4 Ariel Sharon
Read more →SPRCBiosciences Reports Second Quarter 2017 Financial Results and Provides Business Update
Biosciences Reports Second Quarter 2017 Financial Results and Provides Business Update Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT - TEL AVIV, Israel, August 10, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical stage pha
Read more →SPRCTherapix Biosciences Announces CEO Change
Biosciences Announces CEO Change TEL AVIV, Israel, May 24, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, today announced that following t
Read more →SPRCTherapix Biosciences and the Hannover Medical School Enter into an Investigator-Initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome
Biosciences and the Hannover Medical School Enter into an Investigator-Initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome AVIV, Israel, May 8, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a spec
Read more →SPRCTherapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer AVIV, Israel, May 3, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-bas
Read more →SPRCTherapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology Agreement Paves the Way for Development and Marketing of New Cannabinoid-based Treatment Offerings for Mild Cognitive Impairment a
Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology Paves the Way for Development and Marketing of New Cannabinoid-based Treatment Offerings for Mild Cognitive Impairment and other Neurological Conditions Israel, April 5, 2017 - Therapix Bioscienc
Read more →SPRCTherapix Biosciences Ltd. Announces Full Exercise of Underwriters' Over-Allotment Option Tel-Aviv, Israel
Biosciences Ltd. Announces Full Exercise of Underwriters' Over-Allotment Option Israel, April 3, 2017 - Therapix Biosciences Ltd. (NASDAQ; TASE: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced
Read more →SPRCTherapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares 2,000,000 American Depository Shares Priced at $6.00 per ADS Tel-Aviv, Israel
Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares 2,000,000 American Depository Shares Priced Tel-Aviv, Israel, March 27, 2017 - Therapix Biosciences Ltd. (NASDAQ: TRPX, TASE: THXBY), a specialty clinical-stage pharmaceu
Read more →Competitive Position
How SPRC ranks across every disease it competes inCompetitive Position is a premium feature
See how SPRC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial